Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993
Debt
Debt-to-Equity RatioN/A
Current Ratio12.64
Quick Ratio12.63
Price-To-Earnings
Trailing P/E Ratio-6.72
Forward P/E Ratio-6.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales472.61
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book4.69
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-63.20%
Return on Assets-42.19%
Miscellaneous
Employees21
Outstanding Shares13,170,000
Market Cap$165.40
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) issued its quarterly earnings data on Friday, April, 27th. The company reported ($0.37) EPS for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.15. View Spring Bank Pharmaceuticals' Earnings History.
What price target have analysts set for SBPH?
4 brokers have issued 12 month price targets for Spring Bank Pharmaceuticals' shares. Their forecasts range from $30.00 to $32.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $30.6667 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View Analyst Ratings for Spring Bank Pharmaceuticals.
What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include Kura Oncology (KURA), Aptinyx (APTX), Urogen Pharma (URGN), Arbutus Biopharma (ABUS), Odonate Therapeutics (ODT), Aclaris Therapeutics (ACRS), Cara Therapeutics (CARA), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), ChemoCentryx (CCXI), Obseva (OBSV), TIGENIX/S (TIG), Five Prime Therapeutics (FPRX), Beyondspring (BYSI) and Geron (GERN).
Who are Spring Bank Pharmaceuticals' key executives?
Spring Bank Pharmaceuticals' management team includes the folowing people:
- Mr. Martin J. Driscoll, Chairman, Pres & CEO (Age 59)
- Mr. Jonathan P. Freve, CFO & Treasurer (Age 40)
- Dr. Nezam H. Afdhal M.D., Chief Medical Officer (Age 61)
- Dr. Radhakrishna P. Iyer Ph.D., FRSC, Co-Founder, Chief Scientific Officer & Director (Age 68)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
News articles about SBPH stock have trended somewhat negative on Sunday, Accern reports. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of -0.04 on Accern's scale. They also assigned media coverage about the company an impact score of 43.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $12.56.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $165.40 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 21 workers across the globe.
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 86 SOUTH STREET, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
